Generalized Anxiety Disorder clinical trials

Explore recruiting generalized anxiety disorder clinical trials.

Recruiting generalized anxiety disorder studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Generalized Anxiety Disorder trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Modafinil for debilitating fatigue in quiescent inflammatory bowel disease: a multicentre, randomised, double-blind, placebo-controlled, clinical trial (MODIFI-IBD trial)

Netherlands

Phase II and Phase III (Integrated) EU CTIS Study details

A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of ITI-1284 as an Adjunctive Treatment in Patients with Generalized Anxiety Disorder Who Have an Inadequate Response to Generalized Anxiety Disorder Treatment

Czechia, Bulgaria, Poland, Finland

Therapeutic exploratory (Phase II) EU CTIS Study details

A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of ITI-1284 as Monotherapy Treatment in Patients with Generalized Anxiety Disorder Who Have Had Inadequate Response to Generalized Anxiety Disorder Treatment

Poland, Slovakia, Bulgaria, Czechia, Finland

Therapeutic exploratory (Phase II) EU CTIS Study details

A study to examine the effects of oral NTX-1955 on the brain in healthy adults.

Netherlands

Human Pharmacology (Phase I)- Other EU CTIS Study details

CO2 challenge study of NTX-1955 in healthy participants

Netherlands

Human Pharmacology (Phase I)- Other EU CTIS Study details

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, 12-Week Study (Part A) with a 40 Week Open-Label Extension (Part B) Evaluating the Efficacy and Safety of Oral MM120 Compared to Placebo in the Treatment of Adults with Generalized Anxiety Disorder - Panorama

France, Czechia, Germany, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

Generalized Anxiety Disorder trials by city

Generalized Anxiety Disorder in Toronto Generalized Anxiety Disorder in Vancouver Generalized Anxiety Disorder in Montreal Generalized Anxiety Disorder in Calgary Generalized Anxiety Disorder in Edmonton Generalized Anxiety Disorder in Ottawa Generalized Anxiety Disorder in Winnipeg Generalized Anxiety Disorder in Quebec City Generalized Anxiety Disorder in Hamilton Generalized Anxiety Disorder in Kitchener Generalized Anxiety Disorder in London Generalized Anxiety Disorder in Halifax Generalized Anxiety Disorder in New York Generalized Anxiety Disorder in Los Angeles Generalized Anxiety Disorder in Chicago Generalized Anxiety Disorder in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease